IPCA Laboratories

IPCA Laboratories Debt/EBITDA

The Total Debt to EBITDA Ratio of IPCA Laboratories (IPCALAB.NS) as of Nov 2, 2026 is 0.07. In the previous year, Total Debt to EBITDA Ratio was 0.68 — a change of -90.08% (lower).

Debt/EBITDA

0.07

YoY

-90.08%

Last updated:

Total Debt to EBITDA Ratio of IPCA Laboratories is 2026 0.07 . Total Debt to EBITDA Ratio of IPCA Laboratories was 2025 0.68 . It decreases by -90.08% lower compared to the previous year.

The IPCA Laboratories Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
0.49 INR
Jan 1, 2020
0.46 INR
Jan 1, 2021
0.13 INR
Jan 1, 2022
0.60 INR
Jan 1, 2023
1.26 INR
Jan 1, 2024
0.88 INR
Jan 1, 2025
0.68 INR
Jan 1, 2026
0.07 INR
The IPCA Laboratories Debt/EBITDA history
YEARDebt/EBITDAYoY
0.07-90.08%
0.68-23.42%
0.88-30.29%
1.26+110.73%
0.60+366.05%
0.13-72.11%
0.46-6.00%
0.49-50.10%
0.98-19.44%
1.22-39.48%
2.02-25.07%
2.69+151.40%
1.07—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Total Debt to EBITDA Ratio of IPCA Laboratories is 0.07 in 2026.

Total Debt to EBITDA Ratio of IPCA Laboratories changed from 0.68 to 0.07, representing a -90.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — IPCA Laboratories

All Key Metrics — IPCA Laboratories